Navigation Links
Ceregene Reports Data From Parkinson's Disease Phase 2b Study
Date:4/19/2013

#160;                                                       

Ceregene established a leadership position in the fields of gene therapy and neurotrophic factors for the treatment of neurodegenerative diseases. A total of over 100 patients have been safely dosed in two clinical programs: CERE-120 (AAV-NRTN) for Parkinson's disease and CERE-110 (AAV-NGF) for Alzheimer's disease. A randomized, controlled Phase 2 study of CERE-110 for Alzheimer's is continuing. It is fully enrolled and financially supported in large part by a grant from the NIH, with top line data expected by late 2014. In addition to the Parkinson's and Alzheimer's programs, Ceregene has conducted extensive preclinical work with CERE-120 for Huntington's disease, as well as another gene therapy/neurotrophic factor product (AAV-NT4) for blinding ocular diseases (such as Retinitis Pigmentosa, macular degeneration, diabetic retinopathy and glaucoma) and yet another (AAV-IGF1) for Lou Gehrig 's disease (ALS). Ceregene is currently looking at strategic alternatives to advance its AAV gene therapy platform.

About CERE-120 and its Application to Treating Parkinson's Disease
CERE-120 is composed of a harmless adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and restoring function.  Neurturin is a member of the same protein family as glial cell line-derived neurotrophic factor (GDNF).  The two molecules have similar pharmacological properties and both have been shown to benefit the midbrain dopamine neurons that degenera
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... a way to create a highly sensitive chemical sensor ... imperfections have unique electronic properties that the researchers were ... molecules by 300 times. , The study is available ... . , Amin Salehi- Khojin, asst professor of mechanical ... graduate student and Bijandra Kumar, post doc where they ...
(Date:9/22/2014)... Jose, California (PRWEB) September 22, 2014 ... Chitin and chitosan are natural biopolymers available in ... extracted from easily available resources such as shells ... and chitosan is mainly due to the high ... cellulose. Chitosan finds application in various industries owing ...
(Date:9/22/2014)... Mich., Sept. 22, 2014  Neogen Corporation (Nasdaq: ... the first quarter of its 2015 fiscal year, which ... compared to net income of $7,839,000 in the first ... split effective Oct. 30, 2013, earnings per share in ... year ago. First quarter revenues increased 15% ...
(Date:9/22/2014)... , Sept. 22, 2014 Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Robert Bazemore as Chief Operating Officer.  Reporting ... and Chief Executive Officer, Robert will oversee the ... program, sebelipase alfa for LAL Deficiency, and will ...
Breaking Biology Technology:Graphene imperfections key to creating hypersensitive 'electronic nose' 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4
... BEIJING , July 6 /PRNewswire-Asia-FirstCall/ ... the development, assembly, marketing and,sale of medical devices and homecare medical products ... sell 10,000 oxygen-chip units to,Beijing C&D Co., Ltd. for RMB11 million ... , , ...
... XIANYANG, China , July ... ) ("Biostar" or "the Company"), the,Xianyang-based manufacturer of a ... other pharmaceutical products, today,announced that Mr. Deyin "Bill" ... July 1, 2010 . Mr. Chen replaces Ms. ...
... ROCKVILLE, Md. , July 6 Novavax, Inc. ... Gregory Glenn , M.D., as the company,s Chief Scientific Officer ... and Chief Executive Officer of Novavax.  Previously, Dr. Glenn was ... an associate in international health at Johns Hopkins University,s ...
Cached Biology Technology:Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 2Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 3Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 4Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 2Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 2Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 3Novavax Announces Appointment of Dr. Gregory Glenn as Chief Scientific Officer 4
(Date:9/21/2014)... of children with autism are significantly less likely to ... than the mothers of children who are developing normally, ... Institute has found. , Low iron intake was associated ... child if the mother was 35 or older at ... suffered from metabolic conditions such as obesity hypertension or ...
(Date:9/21/2014)... immune T cells may have the ability to trigger ... study led by King,s College London. Although their immune ... may still be able to mount a strong immune ... Nature Medicine . , Our immune system is made ... neutrophils which play an important role in the frontline ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study the ... analysis that could eventually benefit people,s health. The ... manage the energy required to produce the signals used ... generate electric signals at a rate of 500-600 discharges ... required for the electric fish are extreme, but necessary ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Immune system of newborn babies is stronger than previously thought 2
... Biological Sciences Research Council (BBSRC)-led Integrated Biorefining Research and ... which could be used to make biofuel production more ... Issue of the American Chemical Society journal Biochemistry ... the Universities of Warwick and British Columbia, could make ...
... Carolina State University have developed a new technique ... a computer,s ability to build computer models of ... algorithms used to build models of biological systems ... can account for uncertainty and biological variation. This ...
... Institute has won a four-year, $1.9 million grant from ... parasite that causes malaria, laying the groundwork to develop ... "Many antimalarial drugs alleviate symptoms, but do ... malaria parasites are able to persist asymptomatically in the ...
Cached Biology News:First wood-digesting enzyme found in bacteria could boost biofuel production 2New parallelization technique boosts our ability to model biological systems 2Scripps Research scientist wins $1.9 million grant to study malaria 2
Designed for use with the Agencourt SprintPrep 384 kit and all MCPrep reagent kits. Used with flat bottom 96-well microplates such as deep well plates used to culture bacteria....
ID clarifier: non-treated with lid...
... ClearSpin Filter is a novel disposable spin ... clarification of bacterial lysates in plasmid purification ... a novel, disposable spin filtration device especially ... lysates in plasmid purification procedures. The neutralized ...
... (or medium binding) polystyrene surface is ... through passive interactions,• Is suitable primarily ... such as antibodies, that have large ... the surface,• Binding capacity of approximately ...
Biology Products: